62% (tirzepatide) vs 37% (semaglutide) achieved 10% or greater weight loss and 42% (tirzepatide) vs 18% (semaglutide) achieved 15% or greater weight loss within a year
Yes, when taken within recommended dosages, oral glutathione is generally safe
Cutting-edge studies on novel strains, their mechanisms, and potential applications are expected to revolutionize our understanding of their roles in human nutrition and medicine
Although the study was not designed to adequately test for between-group differences in change, we explored differences in between-group effects on GSH concentration using linear mixed models
The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed
No randomized controlled trials have measured the combined effect of NAD plus tirzepatide on body composition, metabolic rate, or long-term weight retention
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
